Haima Therapeutics LLC
Haima Therapeutics is a pre-clinical stage biopharma company focused on developing cell-inspired therapies for the treatment of bleeding and various blood-related diseases. Their lead technology, SynthoPlate, is a novel, fully-synthetic hemostatic agent designed to mitigate bleeding by enhancing the body's natural clotting mechanisms at the site of injury.
Industries
Nr. of Employees
small (1-50)
Haima Therapeutics LLC
11000 Cedar Ave., Ste 280, Cleveland, OH 44106
Products
Synthetic platelet nanoconstruct (IV‑injectable hemostatic agent)
A fully synthetic, intravenously administered nanoparticle therapeutic designed to mimic and amplify platelet adhesion and aggregation to stop bleeding.
Synthetic platelet nanoconstruct (IV‑injectable hemostatic agent)
A fully synthetic, intravenously administered nanoparticle therapeutic designed to mimic and amplify platelet adhesion and aggregation to stop bleeding.
Services
Collaborative development projects and partnerships with government agencies, academia, and industry to advance shelf-stable blood surrogates and hemostatic therapeutics.
Licensing of academic-derived platelet-mimetic technology for commercial development.
Collaborative development projects and partnerships with government agencies, academia, and industry to advance shelf-stable blood surrogates and hemostatic therapeutics.
Licensing of academic-derived platelet-mimetic technology for commercial development.
Expertise Areas
- Preclinical development of hemostatic agents
- Biomimetic nanoparticle engineering
- Liposomal and peptide-functionalized nanoconstructs
- Formulation and scale-up for shelf-stable therapeutics
Key Technologies
- Nanoparticle drug delivery
- Liposomal nanoconstructs
- Peptide ligand functionalization for targeted adhesion
- IV‑injectable hemostatic formulations
News & Updates
Announcement of new appointments to the executive team.
Involvement in a significant project aimed at developing blood substitutes.
Announcement of new appointments to the executive team.
Involvement in a significant project aimed at developing blood substitutes.